Grantham, Mayo, Van Otterloo & Co (GMO)
RNA

Grantham, Mayo, Van Otterloo & Co (GMO)’s Atrium Therapeutics RNA Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Buy
+15,444
New +$217K ﹤0.01% 613

Other funds holding RNA

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
OCAI
O'Connor Alternative Investments New York $1.17B AUM
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s RNA Position: Q1 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) opened a new position in Atrium Therapeutics (RNA) in Q1 2026: 15,444 shares worth $206K. The stake represents ﹤0.01% of the portfolio and ranks #613 among its holdings.

162 funds tracked by Wall St. Rank hold RNA as of Q1 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) held 15,444 shares of Atrium Therapeutics worth $206K as of Q1 2026.
  • Atrium Therapeutics was a new Grantham, Mayo, Van Otterloo & Co (GMO) position in Q1 2026.
  • Atrium Therapeutics made up ﹤0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q1 2026, its #613 holding.
  • 162 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q1 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.